CoChat

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Key Points: Prescribing appropriately for age and cardiovascular risk is likely to result in minimal permanent toxicity-related dasatinib cessation. CML patients on dasatinib with pleural effusion are more likely to have achieved MR4.5 after 6-month therapy than those without effusion.

Overview

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2016003889

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 31 · Cited by 43

Research works printed but not linked: 1

  1. 1940, New Engl J Med, 222, 782

Metadata

Authors
Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., Fleming, S., McQuillan, A., Schwarer, A., Harrup, R., Holmes, A., Ratnasingam, S., Chan, K.-L., Hsu, W.-H., Ashraf, A., Putt, F., & Grigg, A.
Affiliations
  • Epworth Hospital (AU)
  • Austin Hospital (AU)
  • Baker Heart and Diabetes Institute (AU)
  • Royal Adelaide Hospital (AU)
  • Princess Alexandra Hospital (AU)
  • Gosford Hospital (AU)
  • Peter MacCallum Cancer Centre (AU)
  • Monash Health (AU)
  • The Alfred Hospital (AU)
  • Hollywood Medical Centre, Perth, Australia;
  • Box Hill Hospital (AU)
  • Royal Hobart Hospital (AU)
  • Canberra Hospital (AU)
  • The Royal Melbourne Hospital (AU)
  • St Vincent's Hospital Melbourne (AU)
  • Royal Prince Alfred Hospital (AU)
  • Calvary Mater Newcastle Hospital (AU)
Venue
Blood Advances
Published
2017-05-15
Volume
1
Issue
13
Pages
802-811
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2615918143
Cited by
43
References
31
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 10 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 6
FWCI
2.11
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
dasatinib, chronic myeloid leukemia, drug toxicity, pulmonary hypertension, pleural effusion, cytopenia, antiplatelet therapy, dose adjustment, treatment discontinuation, adverse event incidence, natural history (disease)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2016003889
The paper
Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., Fleming, S., McQuillan, A., Schwarer, A., Harrup, R., Holmes, A., Ratnasingam, S., Chan, K.-L., Hsu, W.-H., Ashraf, A., . . . Grigg, A. (2017). The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2016003889

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.